Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Thermo Fisher Scientific Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Thermo Fisher Scientific wird ein jährliches Gewinn- und Umsatzwachstum von 10.6% bzw. 5.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 11.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18% betragen.

Wichtige Informationen

10.6%

Wachstumsrate der Gewinne

11.3%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	0%
Wachstumsrate der Einnahmen	5.6%
Zukünftige Eigenkapitalrendite	18.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	15 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BVL:TMO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	49,501	8,044	8,612	10,484	19
12/31/2025	46,099	6,971	7,902	9,405	25
12/31/2024	43,023	6,146	7,148	8,601	25
3/30/2024	42,492	6,034	7,560	8,928	N/A
12/31/2023	42,857	5,995	6,927	8,406	N/A
9/30/2023	43,421	5,941	6,546	8,170	N/A
7/1/2023	43,524	5,721	5,854	7,693	N/A
4/1/2023	43,807	6,024	5,620	7,681	N/A
12/31/2022	44,915	6,950	6,911	9,154	N/A
10/1/2022	44,167	7,032	5,600	8,124	N/A
7/2/2022	42,820	7,439	6,336	8,837	N/A
4/2/2022	41,123	7,603	7,001	9,536	N/A
12/31/2021	39,211	7,725	6,789	9,312	N/A
10/2/2021	39,059	8,565	7,916	10,194	N/A
7/3/2021	38,250	8,596	8,132	10,252	N/A
4/3/2021	35,894	7,924	8,062	9,911	N/A
12/31/2020	32,218	6,375	6,815	8,289	N/A
9/26/2020	28,497	4,879	5,686	6,863	N/A
6/27/2020	26,248	3,706	4,245	5,272	N/A
3/28/2020	25,647	3,669	3,702	4,680	N/A
12/31/2019	25,542	3,696	4,047	4,973	N/A
9/28/2019	25,220	3,592	3,940	4,861	N/A
6/29/2019	24,868	3,541	4,086	4,964	N/A
3/30/2019	24,630	3,174	4,273	5,114	N/A
12/31/2018	24,358	2,938	3,785	4,543	N/A
9/29/2018	23,898	2,570	3,919	4,608	N/A
6/30/2018	23,094	2,395	3,689	4,317	N/A
3/31/2018	22,006	2,256	3,189	3,722	N/A
12/31/2017	20,918	2,228	N/A	4,005	N/A
9/30/2017	19,824	2,330	N/A	3,344	N/A
7/1/2017	19,199	2,270	N/A	3,220	N/A
4/1/2017	18,744	2,174	N/A	3,284	N/A
12/31/2016	18,274	2,025	N/A	3,258	N/A
10/1/2016	17,973	1,999	N/A	3,281	N/A
7/2/2016	17,606	2,003	N/A	3,220	N/A
4/2/2016	17,341	1,998	N/A	3,072	N/A
12/31/2015	16,965	1,980	N/A	2,942	N/A
9/26/2015	16,806	1,978	N/A	2,543	N/A
6/27/2015	16,854	1,971	N/A	2,475	N/A
3/28/2015	16,905	1,738	N/A	2,598	N/A
12/31/2014	16,890	1,896	N/A	2,620	N/A
9/27/2014	15,864	1,635	N/A	2,394	N/A
6/28/2014	14,884	1,482	N/A	2,224	N/A
3/29/2014	13,802	1,481	N/A	1,814	N/A
12/31/2013	13,090	1,279	N/A	2,011	N/A
9/28/2013	12,883	1,322	N/A	1,942	N/A
6/29/2013	12,777	1,304	N/A	1,917	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: TMODas prognostizierte Gewinnwachstum (10.6% pro Jahr) liegt über der Sparquote (8.4%).

Ertrag vs. Markt: TMODie Erträge des Unternehmens (10.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt PE (19.5% pro Jahr).

Hohe Wachstumserträge: TMODie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: TMODie Einnahmen des Unternehmens (5.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt PE (4.4% pro Jahr).

Hohe Wachstumseinnahmen: TMODie Einnahmen des Unternehmens (5.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: TMODie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (18 %).

Thermo Fisher Scientific Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Thermo Fisher Scientific Inc. Raises Revenue Guidance for the Full Year 2024

Thermo Fisher Scientific Inc. Announces Earnings Guidance for Full Year 2024

Thermo Fisher Scientific Inc. Provides Earnings Guidance for the Year 2023

Thermo Fisher Scientific Inc. Revises earnings Guidance for 2023

Thermo Fisher Scientific Inc. Provides Earnings Guidance for the Full Year 2023

Recent updates

First quarter dividend of US$0.39 announced

Thermo Fisher Scientific Inc. Declares Quarterly Dividend, Payable on July 15, 2024

Thermo Fisher Scientific Introduces Array-Based Solution for Extended Blood Type Research to Support Future Advancements Toward Safer Transfusions

First quarter 2024 earnings released: EPS: US$3.48 (vs US$3.34 in 1Q 2023)

Thermo Fisher Scientific Inc. Raises Revenue Guidance for the Full Year 2024

Thermo Fisher Scientific Inc. Introduces Animal Origin-Free Formulation to Support Scaling of Cell Therapy Manufacturing

Thermo Fisher Scientific Inc., Annual General Meeting, May 22, 2024

Thermo Fisher Scientific Introduces Its Newest Line of High Performance, Ultra-Low Temperature (ULT) Freezers

Thermo Fisher Scientific Inc. to Report Q1, 2024 Results on Apr 24, 2024

Thermo Fisher Scientific Announces A New In-Line Metrology Solution to Improve Battery Safety and Performance

Thermo Fisher Scientific Inc. Launches Corevitas Clinical Registry in Generalized Pustular Psoriasis

Upcoming dividend of US$0.39 per share

New major risk - Share price stability

Fourth quarter dividend increased to US$0.39

Thermo Fisher Scientific Inc. Increases Quarterly Cash Dividend, Payable on April 15, 2024

Thermo Fisher Scientific Inc. Launches New Ion Chromatography Instrument to Improve Reliability, Efficiency, and Functional Adaptability for Labs

Thermo Fisher Scientific Expands GMP Laboratory Service Offerings with Biosafety Testing Including Mycoplasma Testing

Full year 2023 earnings released: EPS: US$15.53 (vs US$17.73 in FY 2022)

Thermo Fisher Scientific Inc. Announces Earnings Guidance for Full Year 2024

Thermo Fisher Scientific Appoints Srinath Venkatesh as Managing Director, India and South Asia

Thermo Fisher Scientific Receives GMP Approval from the Italian Medicines Agency for its Manufacturing Facility of RNA-Based Products in Monza, Italy

Thermo Fisher Scientific Inc. Announces Launch of Innovative Corevitas Pharmacovigilance Platform for Clinical Research Registries

Investor sentiment improves as stock rises 17%

Thermo Fisher Scientific Inc. Announces the Launch of the Thermo Scientific KingFisher Apex Dx and Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit

Upcoming dividend of US$0.35 per share at 0.3% yield

Thermo Fisher Scientific Declares Quarterly Dividend, Payable on January 16, 202

New minor risk - Share price stability

Thermo Fisher Scientific Announces New Fault Localization Solution for the Analysis of Advanced Logic Semiconductors

Thermo Fisher Scientific Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$4.44 (vs US$3.81 in 3Q 2022)

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Thermo Fisher Scientific Inc. to Report Q3, 2023 Results on Oct 25, 2023

Thermo Fisher Scientific Inc. Appoints Jennifer “Jenny” Johnson to the Audit Committee

Thermo Fisher Scientific Helps Accelerate Cell Therapy Manufacturing with A Next-Generation Platform of Gibco™ CTS™ Detachable Dynabeads™

Upcoming dividend of US$0.35 per share at 0.3% yield

Thermo Fisher Scientific Announces the Launch of the EXENT Solution with IVDR Certification

Thermo Fisher Scientific Introduces New Chromosomal Microarray with Two-Day Turnaround Time to Increase Lab Productivity

Thermo Fisher Scientific Inc. (NYSE:TMO) acquired CorEvitas, LLC from Audax Management Company, LLC for approximately $910 million.

Thermo Fisher Scientific Announces a New Line of Thermo Scientific TM TSG Series Refrigerators

Thermo Fisher Scientific Inc. Revises earnings Guidance for 2023

Second quarter 2023 earnings released: EPS: US$3.53 (vs US$4.25 in 2Q 2022)

Thermo Fisher Scientific Introduces New Reproductive Health Assays to Accelerate Fertility Research

Thermo Fisher Scientific Inc. Elects Jenny Johnson to Board of Directors

Thermo Fisher Scientific Inc. (NYSE:TMO) has entered into a definitive agreement to acquire CorEvitas, LLC from Audax Management Company, LLC for Approximately $910 million.

Thermo Fisher May Be Leading Bidder to Buy CorEvitas

Thermo Fisher Scientific Announces Launch of Gibco™ OncoPro™ Tumoroid Culture Medium Kit

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition MarqMetrix, Inc.

Upcoming dividend of US$0.35 per share at 0.3% yield

Thermo Fisher Scientific Introduces Groundbreaking Mass Spectrometer to Revolutionize Biological Discovery

Thermo Fisher Scientific Inc. Declares Quarterly Cash Dividend, Payable on July 14, 2023

Montrose Environmental Group, Inc. Announces Global Collaboration with Thermo Fisher Scientific Inc. to Provide A Comprehensive Real-Time Ethylene Oxide Monitoring Solution Meets Recent Release U.S. Environmental Protection Agency Regulations

Thermo Fisher Scientific Inc., Annual General Meeting, May 24, 2023

Warburg, Advent Reportedly in Lead to Acquire Baxter's Biopharma Unit

First quarter 2023 earnings released: EPS: US$3.34 (vs US$5.65 in 1Q 2022)

Upcoming dividend of US$0.35 per share at 0.3% yield

Thermo Fisher Scientific Launches TrueMark STI Select Panel

Independent Director recently sold US$585k worth of stock

Thermo Fisher Scientific Inc. Provides Earnings Guidance for the Full Year 2023

Full year 2022 earnings released: EPS: US$17.73 (vs US$19.61 in FY 2021)

Thermo Fisher Scientific Inc. Launches CE-IVD Marked Assay to Detect Treatment-Resistant Strains of HIV-1

Thermo Fisher Scientific Inc. to Report Q4, 2022 Results on Feb 01, 2023

Independent Director recently sold US$112k worth of stock

FDA Grants Emergency Use Authorization for Thermo Fisher Scientific's Monkeypox Test

Thermo Fisher Scientific Inc. Announces FDA Grants De Novo Classification to HLA Typing Test for Use as a Companion Diagnostic with a T Cell Receptor Therapy for Metastatic or Unresectable Uveal Melanoma

Thermo Fisher Scientific Launches TrueMark Infectious Disease Research Panels

Upcoming dividend of US$0.30 per share

Thermo Fisher Scientific Introduces All-In-One AAV Production System for Scalable Gene Therapy Workflows and Commercial Applications

Insufficient new directors

Thermo Fisher Scientific Inc. (NYSE:TMO) announces an Equity Buyback for $4,000 million worth of its shares.